Status:
RECRUITING
COVID-19 Coagulopathy Extension Study
Lead Sponsor:
University of Iowa
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
COVID-19
Eligibility:
All Genders
18-99 years
Brief Summary
At the University of Iowa, the investigators led a multicenter randomized clinical trial comparing standard prophylactic dose to intermediate dose enoxaparin in hospitalized patients with COVID-19 (NC...
Detailed Description
1. Background and scientific rationale Infection with the novel coronavirus SARS-CoV-2, first identified in Wuhan, China in late 2019, has become a global pandemic affecting over 209 countries and ter...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Subjects must meet all inclusion criteria in one of the following three categories:
- Acute COVID-19
- Hospital admission for management of symptoms related to COVID-19
- Laboratory confirmed infection with SARS-CoV-2 by either PCR or antigen testing within 4 weeks of hospital admission
- Age ≥18 years
- Incidental COVID-19
- Hospital admission for indications unrelated to COVID-19 who are incidentally found to have infection with SARS-CoV-2
- Age ≥18 years
- Acute influenza
- Hospital admission for clinical management of symptoms related to influenza
- Laboratory confirmed infection with influenza A or influenza B within 4 weeks of hospital admission
- Negative testing for SARS-CoV-2
- Age ≥18 years
- Exclusion criteria
- Current pregnancy
- Prisoner
- History of a bleeding disorder
- Active cancer
Exclusion
Key Trial Info
Start Date :
January 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT05334615
Start Date
January 21 2022
End Date
December 31 2025
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Iowa Health Care
Iowa City, Iowa, United States, 52242